Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds
Epistaxis is the most prevalent clinical symptom in Hereditary Haemorrhagic Telangiectasia (HHT), causing anaemia and decreasing the quality of life (QOL). Since 2013, in Hospital Universitario Fundación Alcorcón, more than 150 HHT patients have been treated by nose sclerotherapy on demand. This stu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/17/3845 |
| _version_ | 1797521232218816512 |
|---|---|
| author | Sol Marcos Luisa María Botella Virginia Albiñana Agustina Arbia Anna María de Rosales |
| author_facet | Sol Marcos Luisa María Botella Virginia Albiñana Agustina Arbia Anna María de Rosales |
| author_sort | Sol Marcos |
| collection | DOAJ |
| description | Epistaxis is the most prevalent clinical symptom in Hereditary Haemorrhagic Telangiectasia (HHT), causing anaemia and decreasing the quality of life (QOL). Since 2013, in Hospital Universitario Fundación Alcorcón, more than 150 HHT patients have been treated by nose sclerotherapy on demand. This study shows the results of 105 patients treated with sclerotherapy between 2017 and 2019. HHT-ESS (epistaxis severity score) was used to measure the severity and frequency of epistaxis. QOL was determined before and after treatment by EuroQol-5D (EQ-5D) and the visual analogue scale (VAS) on the health condition. According to HHT-ESS before treatment, 22 patients presented mild, 35 moderate, and 47 severe epistaxes. Sclerotherapy significantly decreased the frequency and severity of epistaxis, with a significant drop of HHT-ESS in 4.6 points, from 6.23 ± 2.3 to 1.64 ± 1.6. Furthermore, the QOL significantly improved, the EQ-5D scale raised from 0.7 ± 0.26 pre- to 0.92 ± 0.16 post-treatment (<i>p</i> < 0.05). Additionally, VAS mean value showed a significant increase from 4.38 ± 2.4 to 8.35 ± 1.2. The QOL improvement was correlated with the ESS decrease. In conclusion, this study shows that on-demand sclerotherapy at the office significantly reduces HHT epistaxis as well as improved the patients’ QOL. |
| first_indexed | 2024-03-10T08:09:40Z |
| format | Article |
| id | doaj.art-4ad54a45b357427caade4ac9bcb360ff |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T08:09:40Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-4ad54a45b357427caade4ac9bcb360ff2023-11-22T10:48:17ZengMDPI AGJournal of Clinical Medicine2077-03832021-08-011017384510.3390/jcm10173845Sclerotherapy on Demand with Polidocanol to Treat HHT NosebleedsSol Marcos0Luisa María Botella1Virginia Albiñana2Agustina Arbia3Anna María de Rosales4Otorrhinolaringology Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, SpainCIBER Rare Diseases Unit 707, Centro de Investigaciones Biológicas Margarita Salas, CSIC, 28040 Madrid, SpainCIBER Rare Diseases Unit 707, Centro de Investigaciones Biológicas Margarita Salas, CSIC, 28040 Madrid, SpainOtorrhinolaringology Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, SpainPharmaceutical Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, SpainEpistaxis is the most prevalent clinical symptom in Hereditary Haemorrhagic Telangiectasia (HHT), causing anaemia and decreasing the quality of life (QOL). Since 2013, in Hospital Universitario Fundación Alcorcón, more than 150 HHT patients have been treated by nose sclerotherapy on demand. This study shows the results of 105 patients treated with sclerotherapy between 2017 and 2019. HHT-ESS (epistaxis severity score) was used to measure the severity and frequency of epistaxis. QOL was determined before and after treatment by EuroQol-5D (EQ-5D) and the visual analogue scale (VAS) on the health condition. According to HHT-ESS before treatment, 22 patients presented mild, 35 moderate, and 47 severe epistaxes. Sclerotherapy significantly decreased the frequency and severity of epistaxis, with a significant drop of HHT-ESS in 4.6 points, from 6.23 ± 2.3 to 1.64 ± 1.6. Furthermore, the QOL significantly improved, the EQ-5D scale raised from 0.7 ± 0.26 pre- to 0.92 ± 0.16 post-treatment (<i>p</i> < 0.05). Additionally, VAS mean value showed a significant increase from 4.38 ± 2.4 to 8.35 ± 1.2. The QOL improvement was correlated with the ESS decrease. In conclusion, this study shows that on-demand sclerotherapy at the office significantly reduces HHT epistaxis as well as improved the patients’ QOL.https://www.mdpi.com/2077-0383/10/17/3845HHTepistaxissclerotherapypolidocanolpropranololHHT-ESS |
| spellingShingle | Sol Marcos Luisa María Botella Virginia Albiñana Agustina Arbia Anna María de Rosales Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds Journal of Clinical Medicine HHT epistaxis sclerotherapy polidocanol propranolol HHT-ESS |
| title | Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds |
| title_full | Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds |
| title_fullStr | Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds |
| title_full_unstemmed | Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds |
| title_short | Sclerotherapy on Demand with Polidocanol to Treat HHT Nosebleeds |
| title_sort | sclerotherapy on demand with polidocanol to treat hht nosebleeds |
| topic | HHT epistaxis sclerotherapy polidocanol propranolol HHT-ESS |
| url | https://www.mdpi.com/2077-0383/10/17/3845 |
| work_keys_str_mv | AT solmarcos sclerotherapyondemandwithpolidocanoltotreathhtnosebleeds AT luisamariabotella sclerotherapyondemandwithpolidocanoltotreathhtnosebleeds AT virginiaalbinana sclerotherapyondemandwithpolidocanoltotreathhtnosebleeds AT agustinaarbia sclerotherapyondemandwithpolidocanoltotreathhtnosebleeds AT annamariaderosales sclerotherapyondemandwithpolidocanoltotreathhtnosebleeds |